Zentalis Pharmaceuticals
ZNTL
120 hedge funds and large institutions have $1.27B invested in Zentalis Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 22 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 35
0.99% less ownership
Funds ownership: 104.19% → 103.2% (-0.99%)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 122 → 120 (-2)
21% less capital invested
Capital invested by funds: $1.61B → $1.27B (-$345M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$47.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$23.4M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.4M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.97M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$5.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$56.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$15.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.6M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$10.2M |
ZNTL Hedge Fund Activity: Q3 2022 in Review
120 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2022, worth a combined $1.27B — down 21% from $1.61B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ZNTL and 21 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 48 added.
The largest buyer was Wellington Management Group, adding an estimated $47.5M. The largest seller was Viking Global Investors, exiting entirely with an estimated $56.9M sold.
- 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2022, down from 122 in Q2 2022.
- Funds reported $1.27B of Zentalis Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
- 21 funds opened new Zentalis Pharmaceuticals positions in Q3 2022 and 22 closed out, a net change of -1 holder.
- The largest Zentalis Pharmaceuticals buyer in Q3 2022 was Wellington Management Group, an estimated $47.5M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2022 was Viking Global Investors, an estimated $56.9M sold.
Based on aggregated 13F filings for Q3 2022.